SOLICITATION NOTICE
R -- Assistance in Maintaining a Nicotine and Tobacco Addiction Program
- Notice Date
- 7/8/2008
- Notice Type
- Presolicitation
- NAICS
- 541690
— Other Scientific and Technical Consulting Services
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Institute on Drug Abuse, Station Support/Simplified Acquisitions, 31 Center Drive, Room 1B59, Bethesda, Maryland, 20892
- ZIP Code
- 20892
- Solicitation Number
- NOI592807
- Point of Contact
- Susan A Nsangou, Phone: 301-443-2104
- E-Mail Address
-
nsangous@mail.nih.gov
- Small Business Set-Aside
- N/A
- Description
- This is a notice of intent, not a request for a proposal. A solicitation document will not be issued and proposals will not be requested. The National Institute on Drug Abuse intends to negotiate, evaluate, and award a purchase order on a sole source basis to Corrigall Consulting for professional services in the nicotine and addiction research field in the areas of ligand discovery, disease mechanism discovery and model development, and the translation of preclinical discovery to early-stage development. Specifically, Corrigall Consulting will perform the following: Task 1: Monitor, assess and facilitate progress in the National Cooperative Drug Discovery Groups (NCDDG) Initiative in collaboration with NIDA project officers on the cooperative agreement function as Coordinator on all NIDA-funded and NIDA co-funded applications, and assist in planning through participation in regular conference calls with Group investigators face-to-face meetings of the Groups; assist in building a network or consortium of funded applicants from the NCDDG and other related programs, to make the infrastructure in the cooperative agreements available more widely across the groups address gaps that impede progress (e.g., assay availability, access to new technology, behavioral testing) facilitate the translation of new ligands to appropriate next stages of research; link progress in assay development within NCDDG to the NIH Molecular Libraries initiative and the Brain Institute Bioactive Compound Collection, as warranted; link activities within the NCDDG program to other NIDA/NIH funded initiatives as warranted; assist program in working with NIMH and NIAAA, the funding partners in the initiative; suggest funding initiatives to NIDA program staff, such as program announcements to overlay small grants on the funded infrastructure of NCDDG (including advancing the testing of new molecular entities, establishment of screening capabilities specifically related to nicotinic cholinergic receptors, resolving gaps that exist in behavioral testing capacity); assist program in review of progress on RFA/PAR-funded awards and contribute ongoing advice to re-shape the initiative as required. Task 2: Develop the Agenda for, Participate in and/or Chair Scientific Meetings and Workshops in the Nicotine and Tobacco Area that Advance DBNBR Program Efforts, and Represent NIDA Program Activities in Nicotine Addiction at Scientific Meetings Society for Research on Nicotine and Tobacco – European Meeting (SRNT Europe), September 2008, Rome, Italy: organize, chair, and present one of the topic areas in a symposium titled Novel Discovery in Nicotine Neuroscience Research; Society for Neuroscience (SfN), November 2008, Washington, DC: to represent NIDA’s programs in discovery for nicotine addiction; American College on Neuropsychopharmacology (ACNP), December 2008, Scottsdale, AZ: organize a panel symposium titled Nicotinic Cholinergic Receptors in Psychopathology, and act as discussant; Society for Research on Nicotine and Tobacco (SRNT), April 2009, Dublin, Ireland: to represent NIDA’s programs in discovery and development for nicotine and tobacco addiction Task 3: Publish scientific manuscripts relevant to the terms of the contracts, particular on opportunities for the discovery of novel mechanisms of nicotine addiction and on translational science. keep abreast of the relevant scientific literature through attendance at scientific meetings, discussions with scientists in the field, NCDDG interactions, and discussions with NIDA staff; synthesize literature into coherent manuscripts that summarize research progress, that inform NIDA of research gaps and opportunities, and that present forward-looking ideas for research; publish papers in peer-reviewed journals and provide copies to NIDA. Task 4: Support DBNBR/NIDA Efforts in cross-NIDA/NIH Integrative efforts for Nicotine and Tobacco Research as requested, work with DBNBR representative(s) who are engaged in increasing the integration of efforts in nicotine and tobacco research across NIDA and the NIH. as requested, support growth of program efforts by providing input to the development of funding initiatives and scientific meetings in related areas; provide input as requested on trans-NIH efforts that relate to NIDA, such as GPRA activities; provide expertise to model development efforts within DBNBR, at both animal and human experimental levels of analyses; provide other input and opinion to the Director, DBNBR, as might be requested related to the expertise of the contractor, and, keep abreast of NIDA policies and procedures in drug discovery, and attend NIDA panels and advisory boards as warranted. The Contractor will report on the progress of all activities at least monthly to the NIDA Project Officer, by telephone conference call, face-to-face meetings, and/or written form. It is anticipated that the period of performance is one year with 70 hours per month. Corrigall Consulting (William Corrigall) was a research scientist at the Addiction Research Foundation/University of Toronto in Toronto (now the Centre for Addiction and Mental Health) for 25 years. During this time he published seminal work on nicotine addiction using laboratory animal models and human experimental paradigms. He is a past president of the Society for Research on Nicotine and Tobacco. In May 2002, Dr. Corrigall joined NIDA as Chief of the Translational Research Branch and Director of NIDA’s Nicotine and Tobacco Addiction Program. In this latter role, Dr. Corrigall has implemented major efforts that support NIDA’s mission in drug addiction as it relates to tobacco. These include, establishing initiatives in translational (Translating Tobacco Addiction Research to Treatment RFA) and ligand discovery/development research (National Cooperative Drug Discovery Groups for Mood Disorders or Nicotine Addiction RFA), as well as sustaining NIDA’s efforts in transdisciplinary tobacco centers (Transdisciplinary Tobacco Use Research Centers RFA). The acquisition is being conducted under simplified acquisition using FAR 13 procedures and is exempt from the requirements of FAR Part 6, Competition Requirement. This notice of intent is not a request for competitive proposals. Interested parties may identify their interest and capabilities in response to this synopsis. The determination by the Government not to compete the proposed contract based upon responses to this notice is solely with the discretion of the Government.
- Web Link
-
FedBizOpps Complete View
(https://www.fbo.gov/?s=opportunity&mode=form&id=4ac050679577115a6a83e1ad050d3e15&tab=core&_cview=1)
- Place of Performance
- Address: bethesda, Maryland, 20892, United States
- Zip Code: 20892
- Record
- SN01608952-W 20080710/080708221424-4ac050679577115a6a83e1ad050d3e15 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |